Compare ARGX & DG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARGX | DG |
|---|---|---|
| Founded | 2008 | 1939 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1B | 22.4B |
| IPO Year | 2017 | N/A |
| Metric | ARGX | DG |
|---|---|---|
| Price | $856.60 | $136.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 23 |
| Target Price | ★ $971.89 | $129.43 |
| AVG Volume (30 Days) | 336.6K | ★ 4.9M |
| Earning Date | 10-30-2025 | 12-04-2025 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 23.27 | 5.79 |
| Revenue | $3,683,281,000.00 | ★ $42,117,664,000.00 |
| Revenue This Year | $91.22 | $7.83 |
| Revenue Next Year | $36.36 | $4.16 |
| P/E Ratio | $34.12 | ★ $23.60 |
| Revenue Growth | ★ 92.98 | 4.86 |
| 52 Week Low | $510.06 | $66.43 |
| 52 Week High | $934.62 | $137.90 |
| Indicator | ARGX | DG |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 77.67 |
| Support Level | $845.31 | $123.86 |
| Resistance Level | $878.19 | $137.90 |
| Average True Range (ATR) | 17.48 | 4.86 |
| MACD | -9.00 | 1.28 |
| Stochastic Oscillator | 24.47 | 98.00 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.